PHARMADAN A/S
CVR 26524938 · Public limited company (A/S) · Active · Very high risk
PHARMADAN A/S is a Public limited company (A/S), founded on , based in Kastrup. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 7.2% over the next 12 months, which is 5.1 times the average for Danish companies. 20 annual reports have been published. The latest annual report (30 Jun 2025) shows equity of DKK -19.0m and a net result of DKK -5.4m. CEO: Peter Rørvig.
Bankruptcy risk for PHARMADAN A/S
5.1 × the average (1.41%) · higher risk than 95% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 26524938
- Status
- Active
- Company type
- Public limited company (A/S)
- Founded
- (24 years)
- Address
- Englandsvej 350
2770 Kastrup - Municipality
- Tårnby
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 600k
- Auditor
- PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 23 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -854.9% |
| Current ratio | 10% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 5 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -6.4m | DKK -6.2m |
| Net profit | DKK -5.4m | DKK -5.1m |
| Equity | DKK -19.0m | DKK -13.5m |
| Total assets | DKK 2.2m | DKK 6.8m |
| Cash | DKK 406 | – |
| Short-term debt | DKK 21.2m | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jul 2024 – 30 Jun 2025 | 168 | ||
| 1 Jul 2023 – 30 Jun 2024 | 165 | ||
| 1 Jul 2022 – 30 Jun 2023 | 174 | ||
| 1 Jul 2021 – 30 Jun 2022 | 158 | ||
| 1 Jul 2020 – 30 Jun 2021 | 160 | ||
| 1 Jul 2019 – 30 Jun 2020 | 130 | ||
| 1 Jul 2018 – 30 Jun 2019 | 155 | ||
| 1 Jul 2017 – 30 Jun 2018 | 171 | ||
| 1 Jul 2016 – 30 Jun 2017 | 174 | ||
| 1 Jul 2015 – 30 Jun 2016 | 161 | ||
| 1 Jul 2014 – 30 Jun 2015 | 163 | ||
| 1 Jul 2013 – 30 Jun 2014 | 171 | ||
| 1 Jul 2012 – 30 Jun 2013 | 167 | ||
| 1 Jul 2011 – 30 Jun 2012 | 155 | ||
| 1 Jul 2010 – 30 Jun 2011 | 152 | ||
| 1 Jul 2009 – 30 Jun 2010 | 146 | ||
| 1 Jul 2008 – 30 Jun 2009 | 120 | ||
| 1 Jul 2007 – 30 Jun 2008 | 146 | ||
| 1 Jul 2006 – 30 Jun 2007 | 155 | ||
| 1 Jul 2005 – 30 Jun 2006 | 142 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Peter Rørvig | Current | |
| CEO | Niels Otto Thiesen | ||
| Board | Niels Ulrik Heine | Current | |
| Board | Peter Rørvig | Current | |
| Board | Helle Rørvig | Current | |
| Board | Niels Otto Thiesen | ||
| Board | Svend Blankholm | ||
| Owner (100%) | H&P Rørvig Holding A/S | Current | |
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | Current | |
| Auditor | PRICEWATERHOUSECOOPERS SERVICES STATSAUTORISERET REVISIONSAKTIESELSKAB | ||
| Founder | DANIPHARM A/S | Current |
The CEOs' other companies
Peter Rørvig – 9 other companies
- A/S ORTHANA KEMISK FABRIK Active
- BIOFAC A/S Active
- BIOFAC HOLDING A/S Fusioneret
- DANIPHARM A/S Active
- H&P Rørvig Holding A/S Active
- N. THIESEN HOLDING A/S Active
- PHARMADAN ApS Fusioneret
- R & S PHARMADAN ApS Fusioneret
- ZPD A/S Active
Niels Otto Thiesen – 17 other companies, of which 3 bankrupt
- Byrd ApS Bankrupt 17 Nov 2023
- Cuttles ApS Bankrupt 21 Jan 2025
- deepdivr.io ApS Bankrupt 30 Aug 2023
- A/S ORTHANA KEMISK FABRIK Active
- BIOFAC A/S Active
- BIOFAC HOLDING A/S Fusioneret
- Byrd Holding ApS Opløst
- DANIPHARM A/S Active
- EJENDOMSSELSKABET SKÆLSKØR ApS Opløst
- Ejendomsselskabet Glentevej Herning ApS Opløst
- Ejendomsselskabet Klostermuren ApS Active
- H&P Rørvig Holding A/S Active
- Inboxers ApS Opløst
- N. THIESEN HOLDING A/S Active
- PHARMADAN ApS Fusioneret
- R & S PHARMADAN ApS Fusioneret
- TRUSTPILOT A/S Active
Address history (1 moves)
| Englandsvej 350, 2770 Kastrup | |
| Englandsvej 350, 2770 Kastrup |
Other companies at the same address
- A/S ORTHANA KEMISK FABRIK Active
- BIOFAC A/S Active
- BIOFAC HOLDING A/S Fusioneret
- DANIPHARM A/S Active
- PHARMADAN ApS Fusioneret
Similar companies in Tårnby
- FARMACEUTISK LABORATORIUM FERRING A/S Kastrup
- W. RATJE FRØSKALLER ApS Kastrup
Questions and answers about PHARMADAN A/S
Has PHARMADAN A/S gone bankrupt?
No, PHARMADAN A/S is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of PHARMADAN A/S?
Our model estimates a bankruptcy risk of 7.2% over the next 12 months (very high risk), which is 5.1 times the average for Danish companies.
Who is the CEO of PHARMADAN A/S?
Peter Rørvig is the CEO of PHARMADAN A/S.
Who is the auditor of PHARMADAN A/S?
PHARMADAN A/S most recently used PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB.
When was PHARMADAN A/S founded?
PHARMADAN A/S was founded on 27 February 2002.
What is the equity of PHARMADAN A/S?
Equity was DKK -19.0m according to the annual report for the period ending 30 June 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.